| Literature DB >> 33628756 |
Ali Dalir Ghaffari1, Abdolhossein Dalimi1, Fatemeh Ghaffarifar1, Majid Pirestani1, Hamidreza Majidiani1.
Abstract
PURPOSE: Toxoplasmosis, transmitted by Toxoplasma gondii, is a worldwide parasitic disease that affects approximately one-third of the world's inhabitants. Today, there are no appropriate drugs to deter tissue cysts from developing in infected hosts. So, developing an effective vaccine would be valuable to avoid from toxoplasmosis. Considering the role of microneme antigens such as microneme protein 4 (MIC4) in T. gondii pathogenesis, it can be used as potential candidates for vaccine against T. gondii.Entities:
Keywords: Bioinformatics; MIC4 protein; Toxoplasma gondii; Vaccine
Year: 2021 PMID: 33628756 PMCID: PMC7892946 DOI: 10.7774/cevr.2021.10.1.59
Source DB: PubMed Journal: Clin Exp Vaccine Res ISSN: 2287-3651
Fig. 1Bioinformatics analysis of the phosphorylation and acylation locations of the microneme protein 4 (MIC4). (A) If the residue is predicted not to be phosphorylated, either because the score is below the threshold or because the residue is not serine, threonine, or tyrosine, that position is marked by a dot (‘.’). Residues having a prediction score above the threshold are indicated by ‘S’, ‘T’, or ‘Y’, respectively. (B) Expected phosphorylation positions in MIC4 sequence.
The acylation sites of MIC4 sequence
| ID | Position | Peptide | Score |
|---|---|---|---|
| ACY68633.1 MIC4 [ | 12 | LPVHLVVCTQLSAVW | 31.467 |
| ACY68633.1 MIC4 [ | 68 | PAKLDLSCVHSDNKG | 7.601 |
| ACY68633.1 MIC4 [ | 93 | PDVSLEQCAAQCKAV | 1.569 |
| ACY68633.1 MIC4 [ | 97 | LEQCAAQCKAVDGCT | 3.99 |
| ACY68633.1 MIC4 [ | 103 | QCKAVDGCTHFTYND | 7.277 |
| ACY68633.1 MIC4 [ | 115 | YNDDSKMCHVKEGKP | 2.64 |
| ACY68633.1 MIC4 [ | 137 | GKTASRSCDRSCFEQ | 7.705 |
| ACY68633.1 MIC4 [ | 141 | SRSCDRSCFEQHVSY | 0.725 |
| ACY68633.1 MIC4 [ | 166 | VTSQSADCQAACAAD | 2.024 |
| ACY68633.1 MIC4 [ | 170 | SADCQAACAADPSCE | 2.534 |
| ACY68633.1 MIC4 [ | 176 | ACAADPSCEIFTYNE | 6.569 |
| ACY68633.1 MIC4 [ | 188 | YNEHDQKCTFKGRGF | 6.49 |
| ACY68633.1 MIC4 [ | 214 | TSGPKQFCDEGGKLT | 3.175 |
| ACY68633.1 MIC4 [ | 232 | MEDQISGCIQLSDVG | 3.863 |
| ACY68633.1 MIC4 [ | 257 | EADSVGACMERCRCD | 3.423 |
| ACY68633.1 MIC4 [ | 261 | VGACMERCRCDGRCT | 4.003 |
| ACY68633.1 MIC4 [ | 263 | ACMERCRCDGRCTHF | 2.077 |
| ACY68633.1 MIC4 [ | 267 | RCRCDGRCTHFTFND | 9.699 |
| ACY68633.1 MIC4 [ | 279 | FNDNTRMCYLKGDKM | 2.612 |
| ACY68633.1 MIC4 [ | 301 | DRTGPKSCDSSCFSN | 8.477 |
| ACY68633.1 MIC4 [ | 305 | PKSCDSSCFSNGVSY | 5.576 |
| ACY68633.1 MIC4 [ | 332 | EISHPIYCQVICAAN | 1.072 |
| ACY68633.1 MIC4 [ | 336 | PIYCQVICAANPLCT | 2.099 |
| ACY68633.1 MIC4 [ | 342 | ICAANPLCTVFQWYA | 1.86 |
| ACY68633.1 MIC4 [ | 354 | WYASEAKCVVKRKGF | 0.249 |
| ACY68633.1 MIC4 [ | 380 | TVGPREFCDFGGSIR | 1.447 |
| ACY68633.1 MIC4 [ | 419 | DFHDEVECVHTGNIG | 4.389 |
| ACY68633.1 MIC4 [ | 444 | HASSLSECRARCQAE | 1.364 |
| ACY68633.1 MIC4 [ | 448 | LSECRARCQAEKECS | 1.188 |
| ACY68633.1 MIC4 [ | 454 | RCQAEKECSHYTYNV | 5.774 |
| ACY68633.1 MIC4 [ | 466 | YNVKSGLCYPKRGKP | 0.713 |
| ACY68633.1 MIC4 [ | 488 | DMTGSRTCDTSCLRR | 4.209 |
| ACY68633.1 MIC4 [ | 492 | SRTCDTSCLRRGVDY | 9.437 |
| ACY68633.1 MIC4 [ | 517 | YSTLPTDCQVACDAE | 1.031 |
| ACY68633.1 MIC4 [ | 521 | PTDCQVACDAEDACL | 8.059 |
| ACY68633.1 MIC4 [ | 527 | ACDAEDACLVFTWDS | 5.3 |
| ACY68633.1 MIC4 [ | 539 | WDSATSRCYLIGSGF | 7.001 |
| ACY68633.1 MIC4 [ | 565 | VSGPYTFCDNGENLQ | 1.197 |
MIC4, microneme protein 4; T. gondii, Toxoplasma gondii.
Fig. 2Transmembrane helices expected in microneme protein 4 (MIC4). (A) Some statistics and a list of the location of the predicted transmembrane helices and the predicted location of the intervening loop regions. Number of predicted TMHs: the number of predicted transmembrane helices; Exp number of AAs in TMHs: the expected number of amino acids in transmembrane helices. If this number is larger than 18, it is very likely to be a transmembrane protein (or have a signal peptide); Exp number, first 60 AAs: the expected number of amino acids in transmembrane helices in the first 60 amino acids of the protein. If this number more than a few, you should be warned that a predicted transmembrane helix in the N-term could be a signal peptide; Total prob. of N-in: the total probability that the N-term is on the cytoplasmic side of the membrane; Possible N-term signal sequence: a warning that is produced when “Exp number, first 60 AAs” is larger than 10. (B) Analysis of MIC4 transmembrane domain.
Fig. 3Microneme protein 4 (MIC4) secondary structural analysis using GOR IV. (A) Predicted secondary structure. (B) Graphical outcomes of secondary structure prediction of MIC4 protein.
Fig. 4Graphical outcome of vaccine estimation with secondary structure using PSIPRED.
Fig. 5Microneme protein 4 secondary structural analysis using SOMPA. (A) Visualize the prediction; (B) curves for all predicted states.
Secondary structure of the MIC4 protein predicted via GOR IV and SOPMA
| Methods | Alpha-helix region | Extended strand | Beta turn | Random coil |
|---|---|---|---|---|
| GOR IV | 10.17 (59/580) | 28.10 (163/580) | - | 61.72 (358/580) |
| SOPMA | 19.14 (111/580) | 19.31 (112/580) | 5.86 (34/580) | 55.69 (323/580) |
Values are presented as % (number/total number).
MIC4, microneme protein 4; GOR, Garnier-Osguthorpe-Robson.
Disulfide bonds predicted
| Predicted bonds | |
|---|---|
| Disulfide bond scores | |
| 12–115 | VHLVVCTQLSA–DDSKMCHVKEG |
| 68–261 | KLDLSCVHSDN–ACMERCRCDGR |
| 93–141 | VSLEQCAAQCK–SCDRSCFEQHV |
| 97–214 | QCAAQCKAVDG–GPKQFCDEGGK |
| 103–380 | KAVDGCTHFTY–GPREFCDFGGS |
| 137–301 | TASRSCDRSCF–TGPKSCDSSCF |
| 166–267 | SQSADCQAACA–RCDGRCTHFTF |
| 170–354 | DCQAACAADPS–ASEAKCVVKRK |
| 176–257 | AADPSCEIFTY–DSVGACMERCR |
| 188–565 | EHDQKCTFKGR–GPYTFCDNGEN |
| 232–454 | DQISGCIQLSD–QAEKECSHYTY |
| 263–279 | MERCRCDGRCT–DNTRMCYLKGD |
| 305–419 | SCDSSCFSNGV–HDEVECVHTGN |
| 332–488 | SHPIYCQVICA–TGSRTCDTSCL |
| 336–527 | YCQVICAANPL–DAEDACLVFTW |
| 342–466 | AANPLCTVFQW–VKSGLCYPKRG |
| 444–492 | SSLSECRARCQ–TCDTSCLRRGV |
| 448–539 | ECRARCQAEKE–SATSRCYLIGS |
| 517–521 | TLPTDCQVACD–DCQVACDAEDA |
| Predicted connectivity | 1–6, 2–16, 3–8, 4–13, 5–26, 7–20, 9–18, 10–25, 11–15, 12–38, 14–30, 17–19, 21–27, 22–32, 23–36, 24–31, 28–33, 29–37, 34–35 |
Fig. 6Analysis of three-dimensional (3D) structure built with SWISS-MODEL for microneme protein 4 (MIC4). (A) 3D structure prediction of MIC4 protein. (B) Local quality estimate. (C) Comparison with non-redundant set of protein data bank structures. (D) Global quality estimate; (E) Sequence coverage and identity. (F) Model-template alignment.
Fig. 7Validation of three-dimensional (3D) model of microneme protein 4. (A, B) The z-score plot for estimated 3D vaccine structure with ProSA-web server before and after refinement. (C, D) Ramachandran plot analysis of predicted structure. NMR, nuclear magnetic resonance.
B-cell epitopes predicted from Bcepred server
| Prediction parameter | Epitope sequence |
|---|---|
| Flexibility | VSANVTSSEP; SCVHSDNKGSR; CHVKEGK; DLTGGKTASRSCD; CTFKGRG; LGVTSGP; QLYSSPGDRTGPKSCD; GFYKHRK; DFGGSIRDRE; GNIGSKA; LCYPKRGK; GDMTGSRT; FTWDSAT |
| Hydrophilicity | TPAGDDVSANVTSSEPAK; VHSDNKGSRAPT; TYNDDSKMCHVKEGKPD; TGGKTASRSCDRSC; SYEGAPD; VTSQSADCQA; AADPSCE; TYNEHDQKCT; TQEEMEDQ; EEPMEADS; ERCRCDGRCT; YSSPGDRTGPKSCDSSC; VDDPATDVE; SIRDREEADAVGSDDGLNAE; RCQAEKECSH; PKRGKPQ; GDMTGSRTCDTSC; DYSQGPE; ACDAEDAC; DSATSRC; SAHRRNDVDG; DNGENLQ; EAKDTE |
| Accessibility | TSSEPAKLD; HSDNKGSRAPT; THFTYNDDSKM; HVKEGKPDLYDL; GKTASRSCDRS; EQHVSYE; FTYNEHDQKCTFK; SAFKERG; TSGPKQFCDE; GKLTQEEMEDQI; TADLEEPMEADS; TFNDNTRMCYLKGDKMQLYSSPGDRTGPKS; KCVVKRKGFYKHRKTGVT; GSIRDREEADA; NSPDFHDE; RARCQAEKECSHYTYNVKS; CYPKRGKPQFYKYL; RRGVDYSQGPE; GKPWYST; FSAHRRNDVDG; DNGENLQ; LEAKDTE |
| Turns | SCVHSDNKG; FTYNDDSK; HFTFNDNTRM; SCDSSCF; ANSPDFHDE |
| Exposed surface | TYNDDSK; VKEGKPDL; YNEHDQK; QEEMEDQ; KCVVKRKGFYKHRKTG; SIRDREEAD; RCQAEKE; CYPKRGKPQFYKY; EAKDTE |
| Polarity | AKAHGGHRLEPHVP; DDSKMCHVKEGKPDL; RSCFEQHVSYE; TYNEHDQKCTFKGR; FSAFKERG; GKLTQEEMEDQI; DLEEPMEAD; ACMERCRCDGR; AKCVVKRKGFYKHRKTGVT; GSIRDREEADAV; SPDFHDEVECVHT; TIGEVKHASSLSECRARCQAEKECSHYT; CYPKRGKPQF; GFSAHRRNDVDG; LEAKDTE |
| Antigenic propensity | SLPVHLVVCTQLS; HRLEPHVPGFLQ; KLDLSCVHSD; EPVPDVSLEQC; VDGCTHF; SCDRSCFEQHVSY; GVLGVTSG; QISGCIQLSDV; CMERCRCDGRC; KSCDSSCFS; VSYVDDP; VETVFEISHPIYCQVIC; NPLCTVFQWY; KCVVKRKG; GVTGVTVG; HDEVECVHTGNI; ECSHYTYNVKSGLCYPK; PQFYKYL; TCDTSCLRRGV; LPTDCQV; CLVFTWD; TSRCYLIGSG; DVDGVVSGPYT |
B-cell epitopes predicted from ABCpred tool
| Rank | Sequence | Start position | Score |
|---|---|---|---|
| 1 | KGSRAPTIGEPVPDVSLEQC | 74 | 0.90 |
| 2 | PYTFCDNGENLQVLEAKDTE | 561 | 0.88 |
| 2 | FYKHRKTGVTGVTVGPREFC | 361 | 0.88 |
| 3 | SECRARCQAEKECSHYTYNV | 442 | 0.87 |
| 4 | SSEPAKLDLSCVHSDNKGSR | 58 | 0.86 |
| 4 | WYSTLPTDCQVACDAEDACL | 509 | 0.86 |
| 4 | TIGEVKHASSLSECRARCQA | 431 | 0.86 |
| 4 | GVTVGPREFCDFGGSIRDRE | 371 | 0.86 |
| 4 | QWYASEAKCVVKRKGFYKHR | 346 | 0.86 |
| 4 | LTGGKTASRSCDRSCFEQHV | 127 | 0.86 |
| 5 | CYLIGSGFSAHRRNDVDGVV | 539 | 0.85 |
| 6 | FNDNTRMCYLKGDKMQLYSS | 272 | 0.84 |
| 6 | RSCDRSCFEQHVSYEGAPDV | 135 | 0.84 |
| 7 | DAVGSDDGLNAEATMANSPD | 393 | 0.83 |
| 8 | RRNDVDGVVSGPYTFCDNGE | 550 | 0.82 |
| 8 | VKSGLCYPKRGKPQFYKYLG | 461 | 0.82 |
| 8 | CRCDGRCTHFTFNDNTRMCY | 261 | 0.82 |
| 9 | DDPATDVETVFEISHPIYCQ | 314 | 0.81 |
| 10 | PVPDVSLEQCAAQCKAVDGC | 84 | 0.80 |
| 10 | PKRGKPQFYKYLGDMTGSRT | 468 | 0.80 |
| 10 | DFHDEVECVHTGNIGSKAQT | 412 | 0.80 |
| 10 | PMEADSVGACMERCRCDGRC | 248 | 0.80 |
| 10 | CDEGGKLTQEEMEDQISGCI | 214 | 0.80 |
| 10 | CHVKEGKPDLYDLTGGKTAS | 115 | 0.80 |
| 11 | CSHYTYNVKSGLCYPKRGKP | 454 | 0.79 |
| 11 | QGFTDITPAGDDVSANVTSS | 40 | 0.79 |
| 12 | EDACLVFTWDSATSRCYLIG | 524 | 0.78 |
| 12 | LKGDKMQLYSSPGDRTGPKS | 281 | 0.78 |
| 12 | DCQAACAADPSCEIFTYNEH | 165 | 0.78 |
| 13 | LSCVHSDNKGSRAPTIGEPV | 66 | 0.77 |
| 13 | GNIGSKAQTIGEVKHASSLS | 423 | 0.77 |
| 13 | MEDQISGCIQLSDVGSMTAD | 225 | 0.77 |
| 13 | CEIFTYNEHDQKCTFKGRGF | 176 | 0.77 |
| 13 | CTHFTYNDDSKMCHVKEGKP | 103 | 0.77 |
| 14 | SAVWFGVAKAHGGHRLEPHV | 16 | 0.76 |
| 15 | SYEGAPDVMTAMVTSQSADC | 147 | 0.75 |
Fig. 8Linear B-cell epitopes of microneme protein 4 sequence. (A) Percent of accessible residues; (B) alpha-helix; (C) average flexibility; (D) beta-turn; and (E) hydrophobicity.
Linear B-cell epitope of the microneme protein 4 protein by SVMTriP
| Rank | Location | Epitope | Score |
|---|---|---|---|
| 1 | 153–172 | DVMTAMVTSQSADCQAACAA | 1.000 |
| 2 | 475–494 | FYKYLGDMTGSRTCDTSCLR | 0.723 |
| 3 | 250–269 | EADSVGACMERCRCDGRCTH | 0.717 |
| 4 | 347–366 | WYASEAKCVVKRKGFYKHRK | 0.670 |
| 5 | 444–463 | CRARCQAEKECSHYTYNVKS | 0.583 |
| 6 | 393–412 | DAVGSDDGLNAEATMANSPD | 0.562 |
| 7 | 174–193 | PSCEIFTYNEHDQKCTFKGR | 0.528 |
| 8 | 422–441 | TGNIGSKAQTIGEVKHASSL | 0.518 |
The results of linear B-cell epitopes predicted by the Bepipred 1.0 server
| Position | Epitope | Score |
|---|---|---|
| 287 | QLYSSPGDRTGPKSCDSS | 1.304 |
| 71 | SDNKGSRAPTIGEPVPDVSL | 1.224 |
| 44 | DITPAGDDVSANVTSSEPAK | 1.182 |
| 498 | DYSQGPEVGKPWYSTLPT | 1.142 |
| 311 | SYVDDPATDVE | 1.105 |
| 385 | SIRDREEADAVGSDDGLNAEATMANSPDFHD | 1.043 |
| 147 | SYEGAPDV | 0.873 |
| 119 | EGKPDLYDLTGGKTASRSC | 0.845 |
| 205 | GVTSGPKQFCDEGGKLTQEEMEDQ | 0.842 |
| 467 | YPKRGKPQ | 0.824 |
| 240 | SMTADLEEPMEADSV | 0.815 |
| 547 | SAHRRNDVDGVVS | 0.687 |
| 366 | KTGVTGVTVG | 0.645 |
| 424 | NIGSKAQTIGEVK | 0.628 |
| 161 | SQSADCQ | 0.623 |
| 25 | AHGGHRLEPH | 0.584 |
| 183 | EHDQKCT | 0.523 |
Conformational B-cell epitopes of microneme protein 4 protein predicted by ElliPro server
| Residues | No. of residues | Score | Three-dimensional structure |
|---|---|---|---|
| A:Q144, A:H145, A:G150, A:A151, A:P152, A:D153, A:V154, A:D173, A:P174, A:S175, A:C176, A:E177, A:E183, A:G192, A:R193, A:G194, A:F195, A:S196, A:A197, A:F198, A:K199, A:E200, A:R201, A:G202, A:V203, A:L204, A:G205 | 27 | 0.768 | |
| A:S58, A:S59, A:E60, A:P61, A:A62, A:K63, A:L64, A:D65, A:L66, A:H70, A:S71, A:D72, | 46 | 0.665 | |
| A:D138, A:S140, A:C141, A:K211, A:Q212, A:C214, A:D215, A:E216, A:G217, A:G218 | 10 | 0.534 |
Details of selected MHC-I T-cell epitope of Toxoplasma gondii microneme protein 4 protein sequence using IEDB server
| Allele | Start–stop | Peptide sequence | Percentile ranka) |
|---|---|---|---|
| H-2-Kb | 473–482 | PQFYKYLGDM | 2.50 |
| 146–155 | VSYEGAPDVM | 4.70 | |
| 195–204 | FSAFKERGVL | 5.30 | |
| H-2-Db | 304–313 | SCFSNGVSYV | 0.35 |
| 146–155 | VSYEGAPDVM | 1.45 | |
| 335–344 | ICAANPLCTV | 2.25 | |
| H-2-Kd | 347–356 | WYASEAKCVV | 0.65 |
| 311–320 | SYVDDPATDV | 1.05 | |
| 124–133 | LYDLTGGKTA | 1.90 | |
| H-2-Kk | 224–233 | EMEDQISGCI | 1.41 |
| 416–425 | EVECVHTGNI | 4.00 | |
| 317–326 | ATDVETVFEI | 6.20 | |
| H-2-Dd | 373–382 | TVGPREFCDF | 0.11 |
| 466–475 | CYPKRGKPQF | 0.42 | |
| 189–198 | TFKGRGFSAF | 1.10 | |
| H-2-Ld | 35–44 | VPGFLQGFTD | 4.40 |
| 36–45 | PGFLQGFTDI | 7.00 | |
| 473–482 | PQFYKYLGDM | 12.00 |
MHC, major histocompatibility complex.
a)Percentile rank=IC50 value; low percentile rank=high level binding
Details of selected MHC-II T-cell epitope of Toxoplasma gondii microneme protein 4 sequence using IEDB server
| Allele | Start–stop | Peptide sequence | Percentile ranka) |
|---|---|---|---|
| H2-IAd | 151–165 | APDVMTAMVTSQSAD | 0.61 |
| 152–166 | PDVMTAMVTSQSADC | 0.62 | |
| 150–164 | GAPDVMTAMVTSQSA | 0.71 | |
| H2-IAb | 342–356 | CTVFQWYASEAKCVV | 2.05 |
| 343–357 | TVFQWYASEAKCVVK | 2.10 | |
| 341–355 | LCTVFQWYASEAKCV | 2.25 | |
| H2-IEd | 355–369 | VVKRKGFYKHRKTGV | 0.55 |
| 356–370 | VKRKGFYKHRKTGVT | 0.69 | |
| 354–368 | CVVKRKGFYKHRKTG | 0.86 |
MHC, major histocompatibility complex.
a)Percentile rank=IC50 value; low percentile rank=high level binding.
Details of selected MHC-I T-cell epitope of Toxoplasma gondii microneme protein 4 sequence using NetMHCcons server
| Allele | Peptide sequence | IC50 (nM) | % rank | Binding level |
|---|---|---|---|---|
| H-2-Kb | VSYEGAPDVM | 605.05 | 3.0 | WB |
| ISHPIYCQVI | 1,461.36 | 5.0 | WB | |
| FSAFKERGVL | 1,915.27 | 6.0 | WB | |
| H-2-Db | SCFSNGVSYV | 1,044.93 | 0.8 | WB |
| SMTADLEEPM | 1,085.26 | 0.8 | WB | |
| YTFCDNGENL | 1,915.27 | 1.0 | WB | |
| H-2-Kd | CYLKGDKMQL | 226.04 | 0.4 | SB |
| WYASEAKCVV | 314.41 | 0.4 | SB | |
| HYTYNVKSGL | 316.12 | 0.4 | SB | |
| SYVDDPATDV | 449.33 | 0.5 | SB | |
| H-2-Kk | REFCDFGGSI | 47.34 | 0.4 | SB |
| MEADSVGACM | 273.16 | 1.5 | WB | |
| LEEPMEADSV | 386.17 | 1.5 | WB | |
| H-2-Dd | CYPKRGKPQF | 7,366.35 | 1.0 | WB |
| IGEVKHASSL | 7,989.04 | 1.5 | WB | |
| QGPEVGKPWY | 8,387.64 | 1.5 | WB | |
| H-2-Ld | NPLCTVFQWY | 6,719.10 | 2.0 | WB |
| GPKSCDSSCF | 7,527.49 | 2.0 | WB | |
| YPKRGKPQFY | 10,414.04 | 2.0 | WB |
MHC, major histocompatibility complex; SB, strong binders; WB, weak binders.
Details of selected MHC-II T-cell epitope of Toxoplasma gondii microneme protein 4 sequence using NetMHCIIpan server
| Allele | Peptide sequence | IC50 (nM) | % rank | Binding level |
|---|---|---|---|---|
| H2-IAd | GAPDVMTAMVTSQSA | 141.99 | 1.3 | SB |
| APDVMTAMVTSQSAD | 151.69 | 1.5 | SB | |
| PDVMTAMVTSQSADC | 188.39 | 2.5 | WB | |
| H2-IAb | TVFQWYASEAKCVVK | 299.92 | 1.0 | SB |
| CTVFQWYASEAKCVV | 318.79 | 1.1 | SB | |
| VFQWYASEAKCVVKR | 330.76 | 1.1 | SB | |
| H2-IEd | RKGFYKHRKTGVTGV | 1,308.18 | 3.0 | WB |
| VKRKGFYKHRKTGVT | 1,363.38 | 3.0 | WB | |
| KRKGFYKHRKTGVTG | 1,416.20 | 3.0 | WB |
MHC, major histocompatibility complex; SB, strong binders; WB, weak binders.
Predicted microneme protein 4 CTL epitopes using CTLpred server
| Peptide rank | Start position | Sequence | Score (ANN/SVM) |
|---|---|---|---|
| 1 | 357 | KRKGFYKHR | 0.94/1.3198907 |
| 2 | 150 | GAPDVMTAM | 0.64/1.2852105 |
| 3 | 151 | APDVMTAMV | 0.91/0.85639211 |
| 4 | 305 | CFSNGVSYV | 0.99/0.58450796 |
| 5 | 409 | NSPDFHDEV | 0.83/0.73390312 |
| 6 | 171 | AADPSCEIF | 0.76/0.79240508 |
| 7 | 347 | WYASEAKCV | 0.98/0.55196569 |
| 8 | 440 | SLSECRARC | 0.53/0.97958145 |
| 9 | 424 | NIGSKAQTI | 0.93/0.55425176 |
| 10 | 249 | MEADSVGAC | 0.93/0.53702617 |
CTL, cytotoxic-T lymphocyte; ANN, Artificial Neural Network; SVM, Support Vector Machine.
Predicted T- and B-cell dominant epitopes of the microneme protein 4
| Episode | Methods | Location | Sequence | VaxiJen v2.0 value |
|---|---|---|---|---|
| B-cell epitope | ABCpred | 250–258 | EADSVGAC | 1.5601 (probable antigen) |
| Bcepred | 159–166 | VTSQSADC | 1.1042 (probable antigen) | |
| SVMTriP | 444–458 | CRARCQAEKECSHYT | 0.9002 (probable antigen) | |
| Bepipred | 289–300 | YSSPGDRTGPKS | 0.6070 (probable antigen) | |
| CTLpred | 74–80 | KGSRAPT | 0.5586 (probable antigen) | |
| T-cell epitope | IEDB | 357–365 | KRKGFYKHR | 0.7445 (probable antigen) |
| NetMHCcons | 151–158 | APDVMTAM | 0.0556 (probable non-antigen) | |
| NetMHCIIpan | 347–355 | WYASEAKCV | 0.2876 (probable non-antigen) |